Cargando…

mTOR Inhibitors Induce Erythropoietin Resistance in Renal Transplant Recipients

AIM: To elucidate the role of mTOR inhibitors on iron, hepcidin and erythropoietin-mediated regulation of hemopoiesis in stable renal transplant recipients (RTR). BACKGROUND: Impaired hemopoiesis is common following renal transplantation managed using mTOR inhibitors. The mechanisms responsible are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jefferies, Reece, Puttagunta, Harish, Krishnan, Anoushka, Irish, Ashley, Swaminathan, Ramyasuda, Olynyk, John K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901721/ https://www.ncbi.nlm.nih.gov/pubmed/35273970 http://dx.doi.org/10.3389/fmed.2022.722058

Ejemplares similares

Cancer and mTOR inhibitors in kidney transplantation recipients
por: Kao, Chih-Chin, et al.
Publicado: (2018)

Optimising the use of mTOR inhibitors in renal transplantation
por: Russ, Graeme R
Publicado: (2013)

Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience
por: Selvey, Linda A., et al.
Publicado: (2017)

Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?
por: Geissler, Edward K
Publicado: (2015)

Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
por: Wehming, Mathis, et al.
Publicado: (2023)

The Relationship Between Presentation and the Time of Initial Administration of Antibiotics With Outcomes of Peritonitis in Peritoneal Dialysis Patients: The PROMPT Study
por: Muthucumarana, Kalindu, et al.
Publicado: (2016)

Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term Outcomes
por: Kumar, J., et al.
Publicado: (2017)

PRAS40 Is an Integral Regulatory Component of Erythropoietin mTOR Signaling and Cytoprotection
por: Chong, Zhao Zhong, et al.
Publicado: (2012)

Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study
por: Heinze, Georg, et al.
Publicado: (2009)

Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors
por: Zaza, Gianluigi, et al.
Publicado: (2013)

mTOR-Inhibition and COVID-19 in Kidney Transplant Recipients: Focus on Pulmonary Fibrosis
por: Granata, Simona, et al.
Publicado: (2021)

Real-Life Experience of mTOR Inhibitors in Liver Transplant Recipients in a Region Where Living Donation Is Predominant
por: Sung, Pil Soo, et al.
Publicado: (2021)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence
por: Klintmalm, Goran B., et al.
Publicado: (2014)

The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients
por: Murray, Susan L., et al.
Publicado: (2020)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Long-Term Redistribution of Peripheral Lymphocyte Subpopulations after Switching from Calcineurin to mTOR Inhibitors in Kidney Transplant Recipients
por: Llinàs-Mallol, Laura, et al.
Publicado: (2020)

Conversion to mTOR-Inhibitors Plus IV Immunoglobulins in Kidney-Transplant Recipients with BKV Infection: A Retrospective Comparative Study
por: Vela, Carla, et al.
Publicado: (2022)

mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis
por: Xie, Xishao, et al.
Publicado: (2015)

Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review
por: Olszewska, Berenika, et al.
Publicado: (2023)

The Detection of CMV in Saliva Can Mark a Systemic Infection with CMV in Renal Transplant Recipients
por: Waters, Shelley, et al.
Publicado: (2019)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

A Decade of Experience Using mTor Inhibitors in Liver Transplantation
por: Campsen, Jeffrey, et al.
Publicado: (2011)

The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy
por: Geissler, Edward K
Publicado: (2013)

The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma
por: Todeschini, Letizia, et al.
Publicado: (2023)

Evaluation of quantitative changes in regulatory T cells in peripheral blood of kidney transplant recipients with skin cancer after conversion to mTOR inhibitors
por: Cegielska, Agnieszka, et al.
Publicado: (2018)

Optimal use of plasma and urine BK viral loads for screening and predicting BK nephropathy
por: Boan, Peter, et al.
Publicado: (2016)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

Gerosuppression by pan-mTOR inhibitors
por: Leontieva, Olga V., et al.
Publicado: (2016)

mTOR inhibitors in cancer therapy
por: Xie, Jianling, et al.
Publicado: (2016)

mTor Inhibitors for the Treatment of Endometriosis
por: Barra, Fabio, et al.
Publicado: (2018)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Overview of Research into mTOR Inhibitors
por: Mao, Beibei, et al.
Publicado: (2022)

Place of mTOR inhibitors in management of BKV infection after kidney transplantation
por: Jouve, Thomas, et al.
Publicado: (2016)

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
por: Viana, Sofia D., et al.
Publicado: (2018)

Human Cytomegalovirus-Encoded microRNAs Can Be Found in Saliva Samples from Renal Transplant Recipients
por: Waters, Shelley, et al.
Publicado: (2020)

Polymorphisms in mTOR and Calcineurin Signaling Pathways Are Associated With Long-Term Clinical Outcomes in Kidney Transplant Recipients
por: Campos-Salazar, Antony Brayan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ht28fbd8k5hlo3vea499qhqahs